These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 21305609)

  • 1. Regulation of RANKL-induced osteoclastogenesis by TGF-β through molecular interaction between Smad3 and Traf6.
    Yasui T; Kadono Y; Nakamura M; Oshima Y; Matsumoto T; Masuda H; Hirose J; Omata Y; Yasuda H; Imamura T; Nakamura K; Tanaka S
    J Bone Miner Res; 2011 Jul; 26(7):1447-56. PubMed ID: 21305609
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways.
    Li C; Yang Z; Li Z; Ma Y; Zhang L; Zheng C; Qiu W; Wu X; Wang X; Li H; Tang J; Qian M; Li D; Wang P; Luo J; Liu M
    J Bone Miner Res; 2011 Mar; 26(3):644-56. PubMed ID: 20814972
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transforming growth factor beta affects osteoclast differentiation via direct and indirect actions.
    Quinn JM; Itoh K; Udagawa N; Hausler K; Yasuda H; Shima N; Mizuno A; Higashio K; Takahashi N; Suda T; Martin TJ; Gillespie MT
    J Bone Miner Res; 2001 Oct; 16(10):1787-94. PubMed ID: 11585342
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The 4-1BB ligand and 4-1BB expressed on osteoclast precursors enhance RANKL-induced osteoclastogenesis via bi-directional signaling.
    Yang J; Park OJ; Lee YJ; Jung HM; Woo KM; Choi Y
    Eur J Immunol; 2008 Jun; 38(6):1598-609. PubMed ID: 18421790
    [TBL] [Abstract][Full Text] [Related]  

  • 5. JNK/c-Jun signaling mediates an anti-apoptotic effect of RANKL in osteoclasts.
    Ikeda F; Matsubara T; Tsurukai T; Hata K; Nishimura R; Yoneda T
    J Bone Miner Res; 2008 Jun; 23(6):907-14. PubMed ID: 18251700
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epigallocatechin-3-gallate inhibits osteoclastogenesis by down-regulating c-Fos expression and suppressing the nuclear factor-kappaB signal.
    Lee JH; Jin H; Shim HE; Kim HN; Ha H; Lee ZH
    Mol Pharmacol; 2010 Jan; 77(1):17-25. PubMed ID: 19828731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of Nedd9 as a TGF-β-Smad2/3 Target Gene Involved in RANKL-Induced Osteoclastogenesis by Comprehensive Analysis.
    Omata Y; Nakamura S; Koyama T; Yasui T; Hirose J; Izawa N; Matsumoto T; Imai Y; Seo S; Kurokawa M; Tsutsumi S; Kadono Y; Morimoto C; Aburatani H; Miyamoto T; Tanaka S
    PLoS One; 2016; 11(6):e0157992. PubMed ID: 27336669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 12-O-tetradecanoylphorbol-13-acetate (TPA) inhibits osteoclastogenesis by suppressing RANKL-induced NF-kappaB activation.
    Wang C; Steer JH; Joyce DA; Yip KH; Zheng MH; Xu J
    J Bone Miner Res; 2003 Dec; 18(12):2159-68. PubMed ID: 14672351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Licorice isoliquiritigenin suppresses RANKL-induced osteoclastogenesis in vitro and prevents inflammatory bone loss in vivo.
    Zhu L; Wei H; Wu Y; Yang S; Xiao L; Zhang J; Peng B
    Int J Biochem Cell Biol; 2012 Jul; 44(7):1139-52. PubMed ID: 22521613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF-kappaB inhibitor, through downregulation of NFATc1.
    Takatsuna H; Asagiri M; Kubota T; Oka K; Osada T; Sugiyama C; Saito H; Aoki K; Ohya K; Takayanagi H; Umezawa K
    J Bone Miner Res; 2005 Apr; 20(4):653-62. PubMed ID: 15765185
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidermal growth factor receptor regulates osteoclast differentiation and survival through cross-talking with RANK signaling.
    Yi T; Lee HL; Cha JH; Ko SI; Kim HJ; Shin HI; Woo KM; Ryoo HM; Kim GS; Baek JH
    J Cell Physiol; 2008 Nov; 217(2):409-22. PubMed ID: 18543257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genomewide comprehensive analysis reveals critical cooperation between Smad and c-Fos in RANKL-induced osteoclastogenesis.
    Omata Y; Yasui T; Hirose J; Izawa N; Imai Y; Matsumoto T; Masuda H; Tokuyama N; Nakamura S; Tsutsumi S; Yasuda H; Okamoto K; Takayanagi H; Hikita A; Imamura T; Matsuo K; Saito T; Kadono Y; Aburatani H; Tanaka S
    J Bone Miner Res; 2015 May; 30(5):869-77. PubMed ID: 25431176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TRAF2 is essential for TNF-alpha-induced osteoclastogenesis.
    Kanazawa K; Kudo A
    J Bone Miner Res; 2005 May; 20(5):840-7. PubMed ID: 15824857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activated platelets positively regulate RANKL-mediated osteoclast differentiation.
    Weicht B; Maitz P; Kandler B; Fischer MB; Watzek G; Gruber R
    J Cell Biochem; 2007 Dec; 102(5):1300-7. PubMed ID: 17957725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pim-1 regulates RANKL-induced osteoclastogenesis via NF-κB activation and NFATc1 induction.
    Kim K; Kim JH; Youn BU; Jin HM; Kim N
    J Immunol; 2010 Dec; 185(12):7460-6. PubMed ID: 21068407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 2-Methoxystypandrone represses RANKL-mediated osteoclastogenesis by down-regulating formation of TRAF6-TAK1 signalling complexes.
    Chiou WF; Liao JF; Huang CY; Chen CC
    Br J Pharmacol; 2010 Sep; 161(2):321-35. PubMed ID: 20735418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms involved in enhancement of osteoclast formation by activin-A.
    Kajita T; Ariyoshi W; Okinaga T; Mitsugi S; Tominaga K; Nishihara T
    J Cell Biochem; 2018 Aug; 119(8):6974-6985. PubMed ID: 29737562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclic adenosine monophosphate/protein kinase A mediates parathyroid hormone/parathyroid hormone-related protein receptor regulation of osteoclastogenesis and expression of RANKL and osteoprotegerin mRNAs by marrow stromal cells.
    Kondo H; Guo J; Bringhurst FR
    J Bone Miner Res; 2002 Sep; 17(9):1667-79. PubMed ID: 12211438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RGS18 acts as a negative regulator of osteoclastogenesis by modulating the acid-sensing OGR1/NFAT signaling pathway.
    Iwai K; Koike M; Ohshima S; Miyatake K; Uchiyama Y; Saeki Y; Ishii M
    J Bone Miner Res; 2007 Oct; 22(10):1612-20. PubMed ID: 17576169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DICAM inhibits osteoclast differentiation through attenuation of the integrin αVβ3 pathway.
    Jung YK; Han SW; Kim GW; Jeong JH; Kim HJ; Choi JY
    J Bone Miner Res; 2012 Sep; 27(9):2024-34. PubMed ID: 22492581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.